Comera life sciences announces favorable preclinical results of lead sqore excipient in sequrus-2 study

Woburn, mass., oct. 18, 2022 (globe newswire) -- comera life sciences holdings, inc. (nasdaq: cmra), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced favorable results from its recently completed sequrus-2 study. together with the sequrus-1 study, the preclinical results showed that comera's caffeine-based sqore™ excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic (pk) parameters of ipilimumab when administered subcutaneously.
CMRA Ratings Summary
CMRA Quant Ranking